Singapore Molecular Forensics Market Size & Outlook, 2026-2034
Singapore Molecular Forensics Market Insights
- Based on Reed Intelligence findings, the Singapore Molecular Forensics Market reached USD 29.1 Million in 2025 and is estimated to attain USD 65.37 Million by 2034.
- From 2026 to 2034, the Singapore market is expected to grow at a steady CAGR of 9.4%.
- Within the Technology category, PCR-Based Analysis dominated in 2025 in terms of market size contribution.
- Over the forecast period, Next-Generation Sequencing is forecasted to deliver the fastest growth, positioning it as the most lucrative Technology segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, Singapore accounted for 0.35% of the global Molecular Forensics Market size.
- By 2034, United States is expected to lead the global Molecular Forensics Market in terms of market size.
- Within Asia Pacific, China is projected to dominate the regional Molecular Forensics Market size by 2034.
- Japan is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 460.22 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 29.1 Million |
| Market Size In 2034 | USD 65.37 Million |
| Largest segment | PCR-Based Analysis |
| Units | Revenue in USD Million |
| CAGR | 9.4% (2026-2034) |
| Segmnetation Covered | |
| Technology |
|
| Application |
|
| End Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Singapore Molecular Forensics Market Technology 2026-2034 (USD Million)
| Technology | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCR-Based Analysis | XX.x | XX.x | XX.x | 13.45 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Next-Generation Sequencing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Capillary Electrophoresis | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Microarray Technology | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Singapore Molecular Forensics Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Criminal Investigation | XX.x | XX.x | XX.x | 13.1 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Paternity Testing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Biodefense and Pathogen Tracing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Food Authentication | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Wildlife Forensics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Singapore Molecular Forensics Market End Use 2026-2034 (USD Million)
| End Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Government Forensic Laboratories | XX.x | XX.x | XX.x | 11.82 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Private Forensic Laboratories | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Academic and Research Institutions | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Healthcare and Biosurveillance Agencies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.